XML 110 R85.htm IDEA: XBRL DOCUMENT
v3.25.3

SEGMENT INFORMATION (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2025 | Sep. 30, 2024
SEGMENT INFORMATION |  |
Schedule of information regarding operations by segment | Information regarding operations by segment for the three-month period ended June 30, 2025 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | DNA Tagging and | ​ | ​
​ |  | Production |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 160,999 | ​ | $ | 34,263 | ​ | $ | 195,262
Service revenues | ​ |  | 52,070 | ​ | ​ | 57,061 | ​ | ​ | 109,131
Less intersegment revenues | ​ |  | — | ​ |  | — | ​ | ​ | —
Total revenues | ​ | $ | 213,069 | ​ | $ | 91,324 | ​ | $ | 304,393
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | $ | 41,528 | ​ | $ | (36,398) | ​ | $ | 5,130
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ | $ | 1,074,583 | ​ | $ | 119,770 | ​ | $ | 1,194,353
Research and development | ​ | ​ | 705,053 | ​ | ​ | (42,909) | ​ | ​ | 662,144
Total segment operating expenses | ​ | $ | 1,779,636 | ​ | $ | 76,861 | ​ | $ | 1,856,497
Loss from segment operations (a) | ​ | $ | (1,738,108) | ​ | $ | (113,259) | ​ | $ | (1,851,367)
​ Information regarding operations by segment for the three-month period ended June 30, 2024 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services and Kits |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 218,858 | ​ | $ | — | ​ | $ | 27,786 | ​ | $ | 246,644
Service revenues | ​ |  | 59,901 | ​ | ​ | — | ​ | ​ | 166,244 | ​ | ​ | 226,145
Clinical laboratory service revenues | ​ |  | — | ​ | ​ | 325,930 | ​ | ​ | — | ​ | ​ | 325,930
Less intersegment revenues | ​ |  | — | ​ | ​ | (1,200) | ​ | ​ | — | ​ | ​ | (1,200)
Total revenues | ​ | ​ | 278,759 | ​ | ​ | 324,730 | ​ | ​ | 194,030 | ​ | ​ | 797,519
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | ​ | 194,341 | ​ | ​ | (12,260) | ​ | ​ | 63,151 | ​ | ​ | 245,232
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ | $ | 852,919 | ​ | $ | 165,983 | ​ | $ | 604,955 | ​ | $ | 1,623,857
Research and development | ​ | ​ | 660,515 | ​ | ​ | 52,917 | ​ | ​ | 152,149 | ​ | ​ | 865,581
Total segment operating expenses | ​ | $ | 1,513,434 | ​ | $ | 218,900 | ​ | $ | 757,104 | ​ | $ | 2,489,438
Loss from segment operations (a) | ​ | $ | (1,319,093) | ​ | $ | (231,160) | ​ | $ | (693,953) | ​ | $ | (2,244,206)
Information regarding operations by segment for the nine-month period ended June 30, 2025 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | DNA Tagging and | ​ |  |
​ |  | Production |  | Security Products |  | Consolidated
Revenues: | ​ |  |  | ​ |  |  | ​ |  |
Product revenues |  | $ | 668,407 |  | $ | 571,340 | ​ | $ | 1,239,747
Service revenues | ​ | ​ | 159,312 | ​ | ​ | 538,447 | ​ | ​ | 697,759
Clinical laboratory service revenues | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Less intersegment revenues | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Total revenues |  | $ | 827,719 |  | $ | 1,109,787 | ​ | $ | 1,937,506
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit |  | $ | 428,187 |  | $ | 578,700 | ​ | $ | 1,006,887
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ | $ | 2,931,352 | ​ | $ | 1,155,551 | ​ | $ | 4,086,903
Research and development | ​ | ​ | 2,146,426 | ​ | ​ | 138,293 | ​ | ​ | 2,284,719
Total segment operating expenses | ​ | $ | 5,077,778 | ​ | $ | 1,293,844 | ​ | $ | 6,371,622
(Loss) income from segment operations (a) |  | $ | (4,649,591) |  | $ | (715,144) | ​ | $ | (5,364,735)
​ Information regarding operations by segment for the nine-month period ended June 30, 2024 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  |
​ |  | Production |  | Services and Kits |  | Security Products |  | Consolidated
Revenues: | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Product revenues |  | $ | 477,010 | ​ | $ | — | ​ | $ | 470,076 | ​ | $ | 947,086
Service revenues | ​ | ​ | 202,635 | ​ | ​ | — | ​ | ​ | 476,142 | ​ | ​ | 678,777
Clinical laboratory service revenues | ​ | ​ | — | ​ | ​ | 1,004,250 | ​ | ​ | — | ​ | ​ | 1,004,250
Less intersegment revenues | ​ | ​ | — | ​ | ​ | (11,800) | ​ | ​ | — | ​ | ​ | (11,800)
Total revenues |  | $ | 679,645 | ​ | $ | 992,450 | ​ | $ | 946,218 | ​ | $ | 2,618,313
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit |  | $ | 462,464 | ​ | $ | (56,703) | ​ | $ | 366,219 | ​ | $ | 771,980
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment operating expenses | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Selling, general and administrative | ​ | $ | 2,371,501 | ​ | $ | 771,499 | ​ | $ | 1,758,312 | ​ | $ | 4,901,312
Research and development | ​ | ​ | 1,834,551 | ​ | ​ | 198,061 | ​ | ​ | 586,215 | ​ | ​ | 2,618,827
Total segment operating expenses | ​ | $ | 4,206,052 | ​ | $ | 969,560 | ​ | $ | 2,344,527 | ​ | $ | 7,520,139
(Loss) income from segment operations (a) |  | $ | (3,743,588) | ​ | $ | (1,026,263) | ​ | $ | (1,978,308) | ​ | $ | (6,748,159)
(a) | Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.
| Information regarding operations by segment for the twelve- month period ended September 30, 2024 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ | ​ | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 560,000 | ​ | $ | — | ​ | $ | 514,813 | ​ | $ | 1,074,813
Service revenues | ​ |  | 335,354 | ​ | ​ | — | ​ | ​ | 703,323 | ​ | ​ | 1,038,677
Clinical laboratory service revenues | ​ |  | — | ​ | ​ | 1,330,850 | ​ | ​ | — | ​ | ​ | 1,330,850
Less intersegment revenues | ​ |  | — | ​ | ​ | (12,920) | ​ | ​ | — | ​ | ​ | (12,920)
Total revenues | ​ | $ | 895,354 | ​ | $ | 1,317,930 | ​ | $ | 1,218,136 | ​ | $ | 3,431,420
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | $ | 678,166 | ​ | $ | (49,830) | ​ | $ | 388,543 | ​ | $ | 1,016,879
(Loss) income from segment operations (a) | ​ | $ | (4,789,268) | ​ | $ | (1,489,220) | ​ | $ | (2,551,983) | ​ | $ | (8,830,471)
​ Information regarding operations by segment for the twelve- month period ended September 30, 2023 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ | ​ | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Product revenues | ​ | $ | 560,000 | ​ | $ | — | ​ | $ | 658,185 | ​ | $ | 1,218,185
Service revenues | ​ |  | 506,285 | ​ | ​ | — | ​ | ​ | 490,581 | ​ | ​ | 996,866
Clinical laboratory service revenues | ​ |  | — | ​ | ​ | 11,253,312 | ​ | ​ | — | ​ | ​ | 11,253,312
Less intersegment revenues | ​ |  | — | ​ | ​ | (100,920) | ​ | ​ | — | ​ | ​ | (100,920)
Total revenues | ​ | $ | 1,066,285 | ​ | $ | 11,152,392 | ​ | $ | 1,148,766 | ​ | $ | 13,367,443
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross profit | ​ | $ | 748,940 | ​ | $ | 4,409,186 | ​ | $ | 375,306 | ​ | $ | 5,533,432
(Loss) income from segment operations (a) | ​ | $ | (3,792,871) | ​ | $ | 1,206,652 | ​ | $ | (3,550,794) | ​ | $ | (6,137,013)
Schedule of reconciliation of segment loss from operations to corporate (loss) income | Reconciliation of loss from segment operations to Corporate (loss) income for the three-month periods ended June 30, 2025 and 2024 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30,
​ |  | 2025 |  | 2024
Loss from operations of reportable segments | ​ | $ | (1,851,367) | ​ | $ | (2,244,206)
General corporate expenses (b) | ​ |  | (1,842,693) | ​ | ​ | (1,102,485)
Interest income | ​ |  | 40,267 | ​ | ​ | 36,295
Unrealized gain on change in fair value of warrants classified as a liability | ​ |  | 6,410 | ​ | ​ | 5,160,000
Net loss from discontinued operations | ​ | ​ | (336,195) | ​ | ​ | —
Other (expense) income, net | ​ |  | (531) | ​ | ​ | (103)
Consolidated net (loss) income | ​ | $ | (3,984,109) | ​ | $ | 1,849,501
​ Reconciliation of loss from segment operations to Corporate loss for the nine-month periods ended June 30, 2025 and 2024 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30,
​ |  | 2025 |  | 2024
Loss from operations of reportable segments |  | $ | (5,364,735) |  | $ | (6,748,159)
General corporate expenses (b) | ​ | ​ | (4,684,821) | ​ | ​ | (4,005,351)
Interest income | ​ | ​ | 168,672 | ​ | ​ | 84,972
Unrealized gain on change in fair value of warrants classified as a liability | ​ | ​ | 318,840 | ​ | ​ | 9,564,000
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification |  | ​ | — |  | ​ | (394,000)
Transaction costs allocated to warrant liabilities | ​ | ​ | — | ​ | ​ | (633,198)
Loss on issuance of warrants | ​ | ​ | — | ​ | ​ | (1,633,767)
Other (expense) income, net |  | ​ | (23,778) |  | ​ | (9,060)
Net loss from discontinued operations | ​ | ​ | (403,120) | ​ | ​ | —
Consolidated net loss | ​ | $ | (9,988,942) | ​ | $ | (3,774,563)
(b) | General corporate expenses consist of selling, general and administrative expenses that are not specifically identifiable to a segment.
| ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30,
​ |  | 2024 | ​ | 2023
Loss from operations of reportable segments |  | $ | (8,830,471) |  | $ | (6,137,013)
General corporate expenses (b) | ​ |  | (5,194,294) | ​ |  | (4,816,277)
Interest income | ​ |  | 176,301 | ​ |  | 75,332
Unrealized gain on change in fair value of warrants classified as a liability | ​ | ​ | 9,430,000 | ​ | ​ | —
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification | ​ | ​ | (394,000) | ​ | ​ | —
Transaction costs allocated to registered direct offering | ​ | ​ | (633,198) | ​ | ​ | 854,400
Transaction costs allocated to warrant liabilities | ​ | ​ | — | ​ | ​ | —
Loss on issuance of warrants | ​ | ​ | (1,633,767) | ​ | ​ | —
Other income (expense), net | ​ |  | (8,877) | ​ | $ | 642
Consolidated loss before provision for income taxes | ​ | $ | (7,088,306) | ​ | $ | (10,022,916)
(a) | Segment operating loss consists of net sales less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.
(b) | General corporate expenses consists of Selling, general and administrative expenses that are not specifically identifiable to a segment.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration